Lindsey Shapiro, PhD, science writer —

Levels of the tumor necrosis factor receptor-associated factor 6 (TRAF6) protein in immune B-cells are higher than normal in people with myasthenia gravis (MG), and may be a useful biomarker of inflammation in MG, a study suggested. The observed elevations were more pronounced among patients with generalized MG…

Researchers have found that a set of cells called medullary thymic epithelial cells, or mTECs, may play a role in the development of myasthenia gravis (MG) in thymoma patients — people with thymus tumors. Changes in the function of these cells were observed in thymoma tissues collected from people…

Careful administration and monitoring of anesthetic medications may prevent complications in people with subclinical myasthenia gravis (MG) undergoing surgery, a case report suggests. The findings, concerning a woman receiving surgery to remove a thymoma — a tumor of the thymus — suggest that anesthetic management of subclinical MG may…

A man developed signs of myasthenia gravis (MG) with eye symptoms about a month after receiving the first shot of Oxford-AstraZeneca’s COVID-19 vaccine, a case study reports. “This case report implies that COVID-19 vaccination may cause myasthenia gravis with ocular symptoms,” the researchers wrote. “But we should also consider…

European regulators have recommended efgartigimod be approved as an add-on therapy for adults with generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AChR) antibodies. This recommendation, from the Committee for Medicinal Products for Human Use (CHMP), will serve as the basis for a final regulatory decision from the…

Vyvgart (efgartigimod alfa-fcab) is being made available to eligible adults with generalized myasthenia gravis (gMG) in the U.K. under an early access to medicines scheme (EAMS), Argenx, the therapy’s developer, announced. An EAMS is designed to enable access to potentially lifesaving medications for patients with unmet medical…

The U.S. Food and Drug Administration (FDA) has approved Milla Pharmaceuticals’ generic version of Mestinon (pyridostigmine bromide) for treating the symptoms of myasthenia gravis (MG). The new generic, available as a syrup, is expected to soon launch in the U.S. This approval of Milla’s abbreviated new drug…

Rates of long-term disease remission after thymectomy — thymus removal surgery — among people with myasthenia gravis (MG) are lower than rates of remission over the first year after the procedure, according to a real-world study. Most clinical factors, such as disease type, age, or sex were…